Alpha 2.0
Login Register
» Authors » Takashi Fujii

Takashi Fujii

Explore the profile of Takashi Fujii including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 315
Citations 3187
Followers 0
Related Specialties
Oncology
Cardiology & Vascular Diseases
Neurology
Top 10 Co-Authors
Hidenori Oishi
Motoyuki Suzuki
Hiroshi Kunugi
Hiroki Hirayama
Keiichi Namba
Motohiro Hino
Ryu Ishihara
Kenji Yatomi
Soichi Kageyama
Satoru Moriyasu
Published In
J Antibiot (Tokyo)
J Reprod Dev
Int J Clin Oncol
No Shinkei Geka
Circ J
Affiliations
Soon will be listed here.
Recent Articles
1.
Late-onset and relapsed cytokine release syndrome after nivolumab treatment in a patient with head and neck squamous cell carcinoma: a case report
Otsuka T, Kojitani Y, Imamura F, Fukutake J, Nishio M, Fujii T, et al.
Front Oncol . 2025 Feb; 15:1508682. PMID: 39990678
Nivolumab, an anti-programmed death-1 (PD-1) receptor monoclonal antibody, has proven effective in treating platinum-resistant metastatic head and neck squamous cell carcinoma. Immune-related adverse events (irAEs) are well-known complications of PD-1...
2.
Dose-finding and efficacy confirmation trial of the superselective intra-arterial infusion of cisplatin and concomitant radiation therapy for locally advanced maxillary sinus cancer (JCOG1212): final analysis
Shinomiya H, Matsuura K, Onimaru R, Ohkoshi A, Saito Y, Tachibana H, et al.
Int J Clin Oncol . 2025 Feb; 30(3):489-496. PMID: 39913014
Background: JCOG1212 is a dose-finding and efficacy confirmatory study of concurrent superselective intra-arterial infusion of cisplatin and radiotherapy (RADPLAT) for locally advanced primary squamous cell carcinoma of the maxillary sinus...
3.
Impact of preceding treatment for head and neck squamous cell carcinoma on synchronous superficial esophageal squamous cell carcinoma
Ueda T, Ishihara R, Tani Y, Ando Y, Tanabe G, Fujimoto Y, et al.
J Gastroenterol . 2024 Dec; PMID: 39661111
Background: Patients with esophageal squamous cell carcinoma (ESCC) frequently develop synchronous head and neck squamous cell carcinoma (HNSCC). With advances in endoscopic technology and widespread screening of synchronous cancers, the...
4.
His-Bundle Pacing for Pulmonary Hypertension With Bradycardia in Congenital Heart Disease: A Case Report
Takeuchi D, Fujii T, Nishimura T, Inai K, Shoda M
Pacing Clin Electrophysiol . 2024 Oct; 47(12):1637-1641. PMID: 39437194
Bradycardia, atrial tachyarrhythmia, heart failure, residual shunts, and pulmonary hypertension (PH) are significant problems after congenital heart disease surgery. We performed His-bundle pacing (HBP) for drug-resistant PH with bradycardia in...
5.
First-line pembrolizumab with or without chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up of the Japanese population of KEYNOTE‑048
Oridate N, Takahashi S, Tanaka K, Shimizu Y, Fujimoto Y, Matsumoto K, et al.
Int J Clin Oncol . 2024 Oct; 29(12):1825-1839. PMID: 39382718
Background: Previously reported results from phase III KEYNOTE-048 demonstrated similar or improved overall survival (OS) with pembrolizumab or pembrolizumab-chemotherapy versus cetuximab-chemotherapy (EXTREME) in Japanese patients with recurrent/metastatic head and neck...
6.
Impact of Implementation of a Region-Wide Low-Density Lipoprotein Cholesterol Management Clinical Pathway for the Secondary Prevention of Acute Myocardial Infarction
Kurobe M, Baba K, Nunohiro T, Ishizaki M, Furudono S, Nakata T, et al.
Circ J . 2024 Sep; 88(11):1825-1832. PMID: 39284715
Background: Aggressive lipid-lowering therapy is important for secondary prevention of acute myocardial infarction (AMI). The recommended target for low-density lipoprotein cholesterol (LDL-C) of <70 mg/dL is often not achieved. To...
7.
Endoscopic submucosal dissection for lesions developing in the irradiated area of head and neck cancer
Tani Y, Kanesaka T, Urabe K, Korematsu M, Kitamura K, Miyabe J, et al.
J Gastroenterol Hepatol . 2024 Aug; 39(11):2432-2438. PMID: 39152623
Background And Aim: Effective treatment of lesions that develop in the irradiated area of head and neck squamous cell carcinoma is a major concern. This study aimed to clarify the...
8.
Clinical, genomic and immune microenvironmental determinants of nivolumab response in head and neck squamous cell carcinoma
Tsujikawa T, Ohno K, Morita K, Saburi S, Mitsuda J, Yoshimura K, et al.
Front Immunol . 2024 Aug; 15:1390873. PMID: 39136017
Background: In view of improving biomarkers predicting the efficacy of immunotherapy for head and neck squamous cell carcinoma (R/M HNSCC), this multicenter retrospective study aimed to identify clinical, tumor microenvironmental,...
9.
Incidence and risk factors associated with the development of hypothyroidism after postoperative chemoradiotherapy for head and neck cancer patients with high-risk features: Supplementary analysis of JCOG1008
Shimizu H, Kodaira T, Kiyota N, Hayashi R, Nishino H, Asada Y, et al.
Oral Oncol . 2024 Aug; 157():106976. PMID: 39111143
Background And Purpose: Hypothyroidism is a recognized late adverse event following radiotherapy for head and neck cancer (HNC). In the JCOG1008 trial, we treated patients with high-risk HNC with postoperative...
10.
Analysis of lens cloudiness during endoscopic submucosal dissection procedures: Effects of a novel lens cleaner
Fujii T, Watanabe S, Uga M, Matsui Y, Sakaki K, Matsukawa N, et al.
DEN Open . 2024 Jul; 5(1):e416. PMID: 39077550
Objectives: We aimed to identify independent factors for intraoperative endoscopic lens cloudiness during gastric and colorectal endoscopic submucosal dissections, investigate the effectiveness of Cleastay, an endoscope anti-fog solution, and examine...